These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17569878)

  • 1. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure.
    Dückelmann C; Mittermayer F; Haider DG; Altenberger J; Eichinger J; Wolzt M
    Arterioscler Thromb Vasc Biol; 2007 Sep; 27(9):2037-42. PubMed ID: 17569878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure.
    Dückelmann C; Mittermayer F; Haider DG; Altenberger J; Wolzt M
    Transl Res; 2008 Jul; 152(1):24-30. PubMed ID: 18593634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure.
    Hsu CP; Lin SJ; Chung MY; Lu TM
    Atherosclerosis; 2012 Dec; 225(2):504-10. PubMed ID: 23092827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    JAMA; 2011 May; 305(20):2088-95. PubMed ID: 21610241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative prognostic value of plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute destabilized heart failure].
    Manzano-Fernández S; Januzzi JL; Boronat García M; Bonaque-González JC; Muñoz-Esparza C; Albaladejo-Otón MD; Pastor-Pérez FJ; Pastor P; Valdés M; Pascual-Figal DA
    Rev Esp Cardiol; 2011 May; 64(5):365-72. PubMed ID: 21397374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.
    Eurlings LW; Sanders-van Wijk S; van Kraaij DJ; van Kimmenade R; Meeder JG; Kamp O; van Dieijen-Visser MP; Tijssen JG; Brunner-La Rocca HP; Pinto YM
    J Card Fail; 2014 Dec; 20(12):881-90. PubMed ID: 25175696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
    Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender Difference in the Prognostic Value of N-Terminal Pro-B Type Natriuretic Peptide in Patients With Heart Failure　- A Report From the Korean Heart Failure Registry (KorHF).
    Kim HL; Kim MA; Choi DJ; Han S; Jeon ES; Cho MC; Kim JJ; Yoo BS; Shin MS; Seong IW; Ahn Y; Kang SM; Kim YJ; Kim HS; Chae SC; Oh BH; Lee MM; Ryu KH;
    Circ J; 2017 Aug; 81(9):1329-1336. PubMed ID: 28442636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction.
    Kleber ME; Koller L; Goliasch G; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; März W; Niessner A
    Circ Heart Fail; 2015 Jan; 8(1):25-32. PubMed ID: 25342739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure.
    Fu S; Xie L; Li D; Ye P; Luo L
    Clin Interv Aging; 2015; 10():359-65. PubMed ID: 25670892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: results of the SCReening Evaluation of the Evolution of New Heart Failure study (SCREEN-HF).
    McGrady M; Reid CM; Shiel L; Wolfe R; Boffa U; Liew D; Campbell DJ; Prior D; Stewart S; Krum H
    Int J Cardiol; 2013 Oct; 169(2):133-8. PubMed ID: 24080362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
    Amir O; Paz H; Ammar R; Yaniv N; Schliamser JE; Lewis BS
    Isr Med Assoc J; 2008 Feb; 10(2):109-12. PubMed ID: 18432021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study.
    Gaggin HK; Truong QA; Rehman SU; Mohammed AA; Bhardwaj A; Parks KA; Sullivan DA; Chen-Tournoux A; Moore SA; Richards AM; Troughton RW; Lainchbury JG; Weiner RB; Baggish AL; Semigran MJ; Januzzi JL
    Congest Heart Fail; 2013; 19(3):135-42. PubMed ID: 23279139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.
    Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Pedretti RF; Lagioia R; Frigerio M; Catanzaro R; Oliva F
    Int J Cardiol; 2013 Oct; 168(3):2120-6. PubMed ID: 23395457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.